Skip to main content

Omega Fund Management, LLC

13F filer · CIK 0001637359
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$186MU.S. long equity reported on 13F
Positions101 new · 1 closed
Net flow last quarter-$19.6MBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202610 positions
BCAXBicara Therapeutics Inc.$54.1M29.14%2.76%-23.8%Q3 2024
NUVBNuvation Bio Inc.$45.9M24.72%2.33%Not reportedQ1 2021
KMTSKestra Medical Technologies, Ltd.$26M14.00%1.75%Not reportedQ1 2025
BBOTBridgeBio Oncology Therapeutics, Inc.$25.1M13.50%4.11%Not reportedQ3 2025
BBNXBeta Bionics, Inc.$20.6M11.11%2.93%Not reportedQ1 2025
ALMSAlumis Inc.$6.79M3.66%Not reportedNot reportedQ2 2024
SANASana Biotechnology, Inc.$2.94M1.59%0.28%Not reportedQ1 2021
IMAImageneBio, Inc.$2.69M1.45%4.04%Not reportedQ3 2025
ENGNenGene Therapeutics Inc.$1.52M0.82%1.31%Not reportedQ4 2023
ODTXOdyssey Therapeutics, Inc.$54.1K0.03%0.01%NewQ2 2026
Q1 2026Reported May 15, 202610 positions
BCAXBicara Therapeutics Inc.$47.6M29.16%3.65%+8.5%Q3 2024
NUVBNuvation Bio Inc.$34.7M21.25%2.33%Not reportedQ1 2021
BBOTBridgeBio Oncology Therapeutics, Inc.$29.4M18.05%4.11%Not reportedQ3 2025
KMTSKestra Medical Technologies, Ltd.$20.4M12.49%1.75%-25.6%Q1 2025
BBNXBeta Bionics, Inc.$13.2M8.08%2.95%Not reportedQ1 2025
ENGNenGene Therapeutics Inc.$5.97M3.66%1.31%Not reportedQ4 2023
ALMSAlumis Inc.$5.31M3.26%Not reported-63.1%Q2 2024
SANASana Biotechnology, Inc.$2.43M1.49%0.31%Not reportedQ1 2021
IMAImageneBio, Inc.$2.28M1.40%4.07%Not reportedQ3 2025
REPLReplimune Group, Inc.$1.91M1.17%0.30%Not reportedQ3 2018
Q4 2025Reported Feb 17, 202611 positions
NUVBNuvation Bio Inc.$72.4M25.27%2.33%-8.5%Q1 2021
BBOTBridgeBio Oncology Therapeutics, Inc.$41.2M14.37%4.11%Not reportedQ3 2025
BBNXBeta Bionics, Inc.$40.1M14.00%2.97%-31.5%Q1 2025
BCAXBicara Therapeutics Inc.$37.1M12.95%3.90%Not reportedQ3 2024
KMTSKestra Medical Technologies, Ltd.$36.4M12.71%2.35%-16.5%Q1 2025
UPBUpstream Bio, Inc.$36M12.57%2.45%-2.2%Q4 2024
ENGNenGene Therapeutics Inc.$7.91M2.76%1.31%+66.5%Q4 2023
ALMSAlumis Inc.$6.38M2.23%Not reportedNot reportedQ2 2024
SANASana Biotechnology, Inc.$3.43M1.20%0.32%Not reportedQ1 2021
IMAImageneBio, Inc.$3.14M1.10%4.07%Not reportedQ3 2025
REPLReplimune Group, Inc.$2.42M0.84%0.31%Not reportedQ3 2018
Q3 2025Reported Nov 14, 202512 positions
KMTSKestra Medical Technologies, Ltd.$39.1M17.59%3.20%Not reportedQ1 2025
BBNXBeta Bionics, Inc.$38.2M17.16%4.36%-3.4%Q1 2025
BBOTBridgeBio Oncology Therapeutics, Inc.$38.1M17.13%4.15%NewQ3 2025
BCAXBicara Therapeutics Inc.$34.8M15.66%4.04%Not reportedQ3 2024
NUVBNuvation Bio Inc.$32.7M14.69%2.61%-20.0%Q1 2021
UPBUpstream Bio, Inc.$25.5M11.47%2.51%-33.4%Q4 2024
IMAImageneBio, Inc.$3.71M1.67%11.32%NewQ3 2025
ENGNenGene Therapeutics Inc.$3.6M1.62%1.03%Not reportedQ4 2023
SANASana Biotechnology, Inc.$3M1.35%0.32%Not reportedQ1 2021
ALMSAlumis Inc.$2.61M1.17%Not reportedNot reportedQ2 2024
REPLReplimune Group, Inc.$1.04M0.47%0.32%-87.4%Q3 2018
ENGNWenGene Therapeutics Inc.$63.4K0.03%Not reported-72.1%Q4 2023
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.